Datopotamab deruxtecan
- Generic Name
- Datopotamab deruxtecan
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2238831-60-0
- Unique Ingredient Identifier
- GD2OWY1DTK
- Background
Datopotamab deruxtecan is under investigation in clinical trial NCT04656652 (Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)).
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- Drug: Datopotamab deruxtecanDrug: CarboplatinDrug: AZD2936Drug: AZD7789Drug: DurvalumabDrug: MEDI5752
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 371
- Registration Number
- NCT04612751
- Locations
- 🇹🇷
Research Site, Malatya, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath